← Patent-cliff monitor small molecule IDOSE TR TRAVOPROST
Loss of exclusivity February 2031 latest FDA-listed patent expiry
Company Glaukos → See this company's full patent-cliff portfolio Drug detail Brand name IDOSE TR Active ingredient TRAVOPROST Strength 75MCG Dosage form IMPLANT Route INTRACAMERAL Modality Small molecule FDA approval December 2023 Marketing status RX
Listed patents Patent Expires Type 12201555 February 2031 substance, product 11426306 October 2030 product 10206813 October 2030 product 12201557 June 2030 substance, product
Regulatory exclusivity Code Expires NP December 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.